Amyloid-associated depression: A prodromal depression of Alzheimer disease?

Xiaoyan Sun, David C. Steffens, Rhoda Au, Marshal Folstein, Paul Summergrad, Jacqueline Yee, Irwin Rosenberg, D. Mkaya Mwamburi, Qiao Qiu Wei

Research output: Contribution to journalArticle

119 Citations (Scopus)

Abstract

Context: A high ratio of plasma amyloid-β peptide 40 (Aβ40) to Aβ42, determined by both hig hAβ40 and low Aβ42 levels, increases the risk of Alzheimer disease. In a previous study, we reported that depression is also associated with low plasma Aβ42 levels in the elderly population. Objective: To characterize plasma Aβ40: Aβ42 ratio and cognitive function in elderly individuals with and without depression. Design: Cross-sectional study. Setting: Homecare agencies. Participants: A total of 995 homebound elderly individuals of whom 348 were defined as depressed by a Center for Epidemiological Studies Depression score of 16 or greater. Main Outcome Measures: Cognitive domains of memory, language, executive, and visuospatial functions according to levels of plasma Aβ40 and Aβ42 peptides. Results: Subjects with depression had lower plasma Aβ42 levels (median, 14.1 vs 19.2 pg/mL; P=.006) and a higher plasma Aβ40:Aβ42 ratio (median, 8.9 vs 6.4; P<.001) than did those without depression in the absence of cardiovascular disease and antidepressant use. The interaction between depression and plasma Aβ40:Aβ42 ratio was associated with lower memory score (β=-1.9, SE=0.7, P=.006) after adjusting for potentially confounders. Relative to those without depression, "amyloid-associated depression," defined by presence of depression and a high plasma Aβ40:Aβ42 ratio, was associated with greater impairment in memory, visuospatial ability, and executive function; in contrast, nonamyloid depression was not associated with memory impairment but with other cognitive disabilities. Conclusion: Amyloid-associated depression may define a subtype of depression representing a prodromal manifestation of Alzheimer disease.

Original languageEnglish (US)
Pages (from-to)542-550
Number of pages9
JournalArchives of General Psychiatry
Volume65
Issue number5
DOIs
StatePublished - May 2008
Externally publishedYes

Fingerprint

Amyloid
Alzheimer Disease
Depression
Executive Function
Peptides
Aptitude
Cognition
Antidepressive Agents
Epidemiologic Studies
Cardiovascular Diseases
Language
Cross-Sectional Studies
Outcome Assessment (Health Care)
peptide A42

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Sun, X., Steffens, D. C., Au, R., Folstein, M., Summergrad, P., Yee, J., ... Wei, Q. Q. (2008). Amyloid-associated depression: A prodromal depression of Alzheimer disease? Archives of General Psychiatry, 65(5), 542-550. https://doi.org/10.1001/archpsyc.65.5.542

Amyloid-associated depression : A prodromal depression of Alzheimer disease? / Sun, Xiaoyan; Steffens, David C.; Au, Rhoda; Folstein, Marshal; Summergrad, Paul; Yee, Jacqueline; Rosenberg, Irwin; Mwamburi, D. Mkaya; Wei, Qiao Qiu.

In: Archives of General Psychiatry, Vol. 65, No. 5, 05.2008, p. 542-550.

Research output: Contribution to journalArticle

Sun, X, Steffens, DC, Au, R, Folstein, M, Summergrad, P, Yee, J, Rosenberg, I, Mwamburi, DM & Wei, QQ 2008, 'Amyloid-associated depression: A prodromal depression of Alzheimer disease?', Archives of General Psychiatry, vol. 65, no. 5, pp. 542-550. https://doi.org/10.1001/archpsyc.65.5.542
Sun, Xiaoyan ; Steffens, David C. ; Au, Rhoda ; Folstein, Marshal ; Summergrad, Paul ; Yee, Jacqueline ; Rosenberg, Irwin ; Mwamburi, D. Mkaya ; Wei, Qiao Qiu. / Amyloid-associated depression : A prodromal depression of Alzheimer disease?. In: Archives of General Psychiatry. 2008 ; Vol. 65, No. 5. pp. 542-550.
@article{8b56cfca9b1a48e4a02f959a1128d467,
title = "Amyloid-associated depression: A prodromal depression of Alzheimer disease?",
abstract = "Context: A high ratio of plasma amyloid-β peptide 40 (Aβ40) to Aβ42, determined by both hig hAβ40 and low Aβ42 levels, increases the risk of Alzheimer disease. In a previous study, we reported that depression is also associated with low plasma Aβ42 levels in the elderly population. Objective: To characterize plasma Aβ40: Aβ42 ratio and cognitive function in elderly individuals with and without depression. Design: Cross-sectional study. Setting: Homecare agencies. Participants: A total of 995 homebound elderly individuals of whom 348 were defined as depressed by a Center for Epidemiological Studies Depression score of 16 or greater. Main Outcome Measures: Cognitive domains of memory, language, executive, and visuospatial functions according to levels of plasma Aβ40 and Aβ42 peptides. Results: Subjects with depression had lower plasma Aβ42 levels (median, 14.1 vs 19.2 pg/mL; P=.006) and a higher plasma Aβ40:Aβ42 ratio (median, 8.9 vs 6.4; P<.001) than did those without depression in the absence of cardiovascular disease and antidepressant use. The interaction between depression and plasma Aβ40:Aβ42 ratio was associated with lower memory score (β=-1.9, SE=0.7, P=.006) after adjusting for potentially confounders. Relative to those without depression, {"}amyloid-associated depression,{"} defined by presence of depression and a high plasma Aβ40:Aβ42 ratio, was associated with greater impairment in memory, visuospatial ability, and executive function; in contrast, nonamyloid depression was not associated with memory impairment but with other cognitive disabilities. Conclusion: Amyloid-associated depression may define a subtype of depression representing a prodromal manifestation of Alzheimer disease.",
author = "Xiaoyan Sun and Steffens, {David C.} and Rhoda Au and Marshal Folstein and Paul Summergrad and Jacqueline Yee and Irwin Rosenberg and Mwamburi, {D. Mkaya} and Wei, {Qiao Qiu}",
year = "2008",
month = "5",
doi = "10.1001/archpsyc.65.5.542",
language = "English (US)",
volume = "65",
pages = "542--550",
journal = "JAMA Psychiatry",
issn = "2168-622X",
publisher = "American Medical Association",
number = "5",

}

TY - JOUR

T1 - Amyloid-associated depression

T2 - A prodromal depression of Alzheimer disease?

AU - Sun, Xiaoyan

AU - Steffens, David C.

AU - Au, Rhoda

AU - Folstein, Marshal

AU - Summergrad, Paul

AU - Yee, Jacqueline

AU - Rosenberg, Irwin

AU - Mwamburi, D. Mkaya

AU - Wei, Qiao Qiu

PY - 2008/5

Y1 - 2008/5

N2 - Context: A high ratio of plasma amyloid-β peptide 40 (Aβ40) to Aβ42, determined by both hig hAβ40 and low Aβ42 levels, increases the risk of Alzheimer disease. In a previous study, we reported that depression is also associated with low plasma Aβ42 levels in the elderly population. Objective: To characterize plasma Aβ40: Aβ42 ratio and cognitive function in elderly individuals with and without depression. Design: Cross-sectional study. Setting: Homecare agencies. Participants: A total of 995 homebound elderly individuals of whom 348 were defined as depressed by a Center for Epidemiological Studies Depression score of 16 or greater. Main Outcome Measures: Cognitive domains of memory, language, executive, and visuospatial functions according to levels of plasma Aβ40 and Aβ42 peptides. Results: Subjects with depression had lower plasma Aβ42 levels (median, 14.1 vs 19.2 pg/mL; P=.006) and a higher plasma Aβ40:Aβ42 ratio (median, 8.9 vs 6.4; P<.001) than did those without depression in the absence of cardiovascular disease and antidepressant use. The interaction between depression and plasma Aβ40:Aβ42 ratio was associated with lower memory score (β=-1.9, SE=0.7, P=.006) after adjusting for potentially confounders. Relative to those without depression, "amyloid-associated depression," defined by presence of depression and a high plasma Aβ40:Aβ42 ratio, was associated with greater impairment in memory, visuospatial ability, and executive function; in contrast, nonamyloid depression was not associated with memory impairment but with other cognitive disabilities. Conclusion: Amyloid-associated depression may define a subtype of depression representing a prodromal manifestation of Alzheimer disease.

AB - Context: A high ratio of plasma amyloid-β peptide 40 (Aβ40) to Aβ42, determined by both hig hAβ40 and low Aβ42 levels, increases the risk of Alzheimer disease. In a previous study, we reported that depression is also associated with low plasma Aβ42 levels in the elderly population. Objective: To characterize plasma Aβ40: Aβ42 ratio and cognitive function in elderly individuals with and without depression. Design: Cross-sectional study. Setting: Homecare agencies. Participants: A total of 995 homebound elderly individuals of whom 348 were defined as depressed by a Center for Epidemiological Studies Depression score of 16 or greater. Main Outcome Measures: Cognitive domains of memory, language, executive, and visuospatial functions according to levels of plasma Aβ40 and Aβ42 peptides. Results: Subjects with depression had lower plasma Aβ42 levels (median, 14.1 vs 19.2 pg/mL; P=.006) and a higher plasma Aβ40:Aβ42 ratio (median, 8.9 vs 6.4; P<.001) than did those without depression in the absence of cardiovascular disease and antidepressant use. The interaction between depression and plasma Aβ40:Aβ42 ratio was associated with lower memory score (β=-1.9, SE=0.7, P=.006) after adjusting for potentially confounders. Relative to those without depression, "amyloid-associated depression," defined by presence of depression and a high plasma Aβ40:Aβ42 ratio, was associated with greater impairment in memory, visuospatial ability, and executive function; in contrast, nonamyloid depression was not associated with memory impairment but with other cognitive disabilities. Conclusion: Amyloid-associated depression may define a subtype of depression representing a prodromal manifestation of Alzheimer disease.

UR - http://www.scopus.com/inward/record.url?scp=43149101276&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=43149101276&partnerID=8YFLogxK

U2 - 10.1001/archpsyc.65.5.542

DO - 10.1001/archpsyc.65.5.542

M3 - Article

C2 - 18458206

AN - SCOPUS:43149101276

VL - 65

SP - 542

EP - 550

JO - JAMA Psychiatry

JF - JAMA Psychiatry

SN - 2168-622X

IS - 5

ER -